Bertrand Cariou Articles
PCSK9 and the beta-cell
PCSK9 is expressed in human pancreatic islets, where it down-regulates LDLR expression. But what are the effects of PCSK9-deficiency on glucose homeostasis and insulin secretion? Dr Betrand Cariou (l’Institut du Thorax Université de Nantes, France) overviews the evidence from studies to date.
read more »
ORION-1: inclisiran shows sustained LDL cholesterol lowering with 2 doses
ESC 2017: Further data from the ORION-1 trial, first reported earlier this year, showed a sustained and durable LDL cholesterol lowering response extending to Day 360 after one or two doses (1,2). Inclisiran is a novel siRNA inhibitor to PCSK9 which specifically targets intracellular PCSK9…
read more »
PCSK9 inhibition and glucose homeostasis: new reassurance from human genetics
INSERM, UMR1087-CNRS UMR6291 & Université de Nantes, Faculté de Médecine, l’Institut du Thorax, and Department of Endocrinology, University Hospital of Nantes, Nantes, France The role of PCSK9 in glucose homeostasis is a critical issue, especially for the PCSK9 inhibitors (1), which are likely to be…
read more »
Does PCSK9 have effects beyond the liver and if so, what is the evidence?
Laboratory research conducted in France shows that PCSK9 may have effects beyond its primary action in the liver, where its inhibition significantly lowers low density lipoprotein cholesterol (LDL-C). These studies also provide reassuring data about the probable safety of these new therapies, Professor Bertrand Cariou…
read more »
Evidence for the effects of PCSK9 beyond the liver
Evidence for the effects of PCSK9 beyond the liver was discussed by Professor Bertrand Cariou, INSERM UMR1087, l’Institut du Thorax, Nantes, France. A seminal paper showed that PCSK9 exerts hypocholesterolaemic effects via action in both the liver and intestine; in the latter case, PCSK9 modulates…
read more »
